The Inflammation Intelligence Company
Standard tests measure inflammation. We measure the part that acts.
C-reactive protein circulates as an inactive pentamer. It is the monomeric form — mCRP — that binds tissue and drives the inflammatory cascade. Sentos BioMed is building the first aptamer-based platform designed to quantify mCRP specifically, with greater than 95% discrimination from the pentameric form.
Development-stage in-vitro diagnostic. For Research Use Only.
- Founded on doctoral research
- Aptamer-based
- Patent-pending
- Chennai, India
The problem
The most-ordered inflammation test can't see the active molecule
For decades, clinicians have measured total or pentameric CRP (pCRP) as a general marker of inflammation. But pCRP is largely a circulating, inactive reservoir. When inflammation localises in tissue, pCRP dissociates into monomeric CRP (mCRP) — the pro-inflammatory form that binds membranes, activates platelets and endothelium, and amplifies the local response. Conventional assays don’t distinguish the two, so the clinically active signal is averaged away.
Supported: specificity data
What we're building
A specific readout for the active form of inflammation
Our lead product, the mCRP-ALISA™ assay, uses a proprietary DNA aptamer raised specifically against native human mCRP. In a competitive Aptamer-Linked Immuno-Sorbent Assay (ALISA) format, it delivers a quantitative mCRP measurement from a low volume sample. Aptamers are chemically synthesised, highly reproducible, and more thermally robust than antibodies — advantages that matter for cost, scale, and use in warm climates.
01
Specific
02
Practical
03
Scalable
Evidence
Signal where it matters — across four inflammatory conditions
In exploratory clinical cohorts, mCRP was elevated in patients versus controls across chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), major depressive disorder (MDD), and obesity. The most striking research observation: in the MDD cohort, mCRP was elevated without a corresponding rise in conventional CRP — a signal standard testing would miss entirely.
Exploratory research findings in limited cohorts. Not established for clinical diagnosis.
Beyond the test
A product, a platform, and an intelligence layer
The kit is the beginning. The same measurement becomes a platform for inflammation monitoring across diseases and settings, and — over time, with appropriate consent and governance — a longitudinal intelligence layer that makes inflammation trackable rather than merely detectable.
Who we serve
Built for four audiences at once
Let’s talk about measuring what matters.
Whether you run a lab, build inflammation therapeutics, or invest in diagnostics, we’d like to hear from you.